FindTrial
Sign In

Multi-parameter and Radiomics Combined with Clinical Features of 18F-FDGPET/CT: A Single-center Clinical Study (Retrospective Clinical Study) on Efficacy Evaluation and Risk Stratification Prediction Model Construction for Diffuse Large B-Cell Lymphoma Treated with Polatuzumab-containing Regimens

Multi-parameter and Radiomics Combined with Clinical Features of 18F-FDGPET/CT: A Single-center Clinical Study (Retrospective Clinical Study) on Efficacy Evaluation and Risk Stratification Prediction Model Construction for Diffuse Large B-Cell Lymphoma Treated with Polatuzumab-containing Regimens

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125211
Enrollment
Unknown
Registered
2026-05-22
Start date
2026-05-22
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

Modeling group:none
Validation group:none

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Confirmed diagnosis of diffuse large B-cell lymphoma; 2. ¹8F-FDG PET/CT examination was performed before Pola therapy; 3. Complete clinicopathological and follow-up data are available.

Exclusion criteria

Exclusion criteria: 1. Complicated with other diseases that severely affect FDG uptake (such as other tumors, active infections, etc.); 2. Poor image quality; 3. Severe lack of clinical and follow-up data.

Design outcomes

Primary

MeasureTime frame
receiver operating characteristic curve, ROC;Progression-Free Survival;Overall Survival;—

Countries

China

Contacts

Public ContactTian Rong

West China Hospital of Sichuan University

rongtiannuclear@126.com+86 189 8060 1586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026